(Total Views: 446)
Posted On: 09/04/2023 2:07:18 PM
Post# of 154115
Re: Evil Rabbit #136977
A big question may be how will the hiring of a new CEO impact the trials strategy going forward.
Seems like an experienced CEO would want to thoroughly review the situation with Cyrus, the clinical team and Dr Hansen to potentially create a new plan, especially with multiple indications in play.
Obviously that could depend on when the hold is lifted, how close NASH is to being started (what work has been done with the FDA's hepatology division) and of course when the new CEO is hired but with everything ahead of us, there is the possibility that a new CEO will advocate for an revised plan.
Seems like an experienced CEO would want to thoroughly review the situation with Cyrus, the clinical team and Dr Hansen to potentially create a new plan, especially with multiple indications in play.
Obviously that could depend on when the hold is lifted, how close NASH is to being started (what work has been done with the FDA's hepatology division) and of course when the new CEO is hired but with everything ahead of us, there is the possibility that a new CEO will advocate for an revised plan.
(2)
(0)
